RESUMO
BACKGROUND: The nucleoside analog cytarabine (Ara-C [cytosine arabinoside]) is the key agent for treating acute myeloid leukemia (AML); however, up to 30% of patients fail to respond to treatment. Screening of patient blood samples to determine drug response before commencement of treatment is needed. This project aimed to construct and evaluate a self-bioluminescent reporter strain of Escherichia coli for use as an Ara-C biosensor and to design an in vitro assay to predict Ara-C response in clinical samples. METHODS: We used transposition mutagenesis to create a cytidine deaminase (cdd)-deficient mutant of E. coli MG1655 that responded to Ara-C. The strain was transformed with the luxCDABE operon and used as a whole-cell biosensor for development an 8-h assay to determine Ara-C uptake and phosphorylation by leukemic cells. RESULTS: Intracellular concentrations of 0.025 µmol/L phosphorylated Ara-C were detected by significantly increased light output (P < 0.05) from the bacterial biosensor. Results using AML cell lines with known response to Ara-C showed close correlation between the 8-h assay and a 3-day cytotoxicity test for Ara-C cell killing. In retrospective tests with 24 clinical samples of bone marrow or peripheral blood, the biosensor-based assay predicted leukemic cell response to Ara-C within 8 h. CONCLUSIONS: The biosensor-based assay may offer a predictor for evaluating the sensitivity of leukemic cells to Ara-C before patients undergo chemotherapy and allow customized treatment of drug-sensitive patients with reduced Ara-C dose levels. The 8-h assay monitors intracellular Ara-CTP (cytosine arabinoside triphosphate) levels and, if fully validated, may be suitable for use in clinical settings.
Assuntos
Antimetabólitos Antineoplásicos/farmacologia , Técnicas Biossensoriais , Citarabina/análise , Escherichia coli , Leucemia Mieloide Aguda/sangue , Leucemia Mieloide Aguda/patologia , Células da Medula Óssea/efeitos dos fármacos , Células da Medula Óssea/patologia , Linhagem Celular Tumoral , Citarabina/farmacologia , Citidina Desaminase , Desoxicitidina Quinase/biossíntese , Desoxicitidina Quinase/genética , Resistencia a Medicamentos Antineoplásicos , Escherichia coli/efeitos dos fármacos , Escherichia coli/genética , Humanos , Espaço Intracelular/química , Leucemia Mieloide Aguda/tratamento farmacológico , Medições Luminescentes , Mutação , Nucleosídeo Desaminases/genética , FosforilaçãoRESUMO
This study assesses whether the kinetic response of AML cells to HGFs might help to predict initial clinical outcome of treatment in de novo AML in association with age, FAB type and karyotype. Best subset regression analysis indicated optimal variables to develop models to predict prognosis. High S-phase in surviving cells following 7 days incubation in SFM, resistance to stimulation by G+GM-CSF and poor karyotype taken in combination correctly predicted outcome in 83% of patients. The importance of high SFM S-phase may be to indicate autonomous proliferation therefore a leukemic clone more likely to regenerate following therapy at the expense of normal haemopoiesis. Kinetic studies of AML cells may be a useful predictor of outcome in addition to other more established prognostic factors.
Assuntos
Leucemia Mieloide Aguda/patologia , Fase S , Adulto , Idoso , Divisão Celular/efeitos dos fármacos , Hematínicos/farmacologia , Humanos , Pessoa de Meia-Idade , Valor Preditivo dos Testes , PrognósticoRESUMO
This study used cDNA microarray technology to compare gene expression profiles in acute myeloblastic leukaemia (AML) with cDNA dot-blot and real time PCR analysis of cDNA transcripts to confirm array data. Patient AML marrow samples and AML cell lines were compared with normal/non-AML samples. Screening revealed five particular genes to be significantly differentially expressed across the sample groups. The migration-inhibitory factor-related-proteins 8 and 14 (MRP-8 and MRP-14) genes, the products of which inhibit cell migration and differentiation were the most highly expressed in non-malignant cells. The high-mobility-group-protein gene (HMG-1) was up regulated in leukaemic samples and cell lines, which may be associated with aggressive disease. Also upregulated in malignant samples were genes encoding c-myc and glutathione-S-transferase pi (GSTP), the latter implicated in chemotherapy resistance. Faulty expression of such genes may contribute to the pathogenesis of AML and resistance to treatment.
Assuntos
Regulação Neoplásica da Expressão Gênica , Leucemia Mieloide Aguda/patologia , Análise de Sequência com Séries de Oligonucleotídeos , Adulto , Idoso , Biópsia , Medula Óssea/patologia , Linhagem Celular Tumoral , Perfilação da Expressão Gênica , Glutationa Transferase/biossíntese , Glutationa Transferase/genética , Proteína HMGB1/biossíntese , Proteína HMGB1/genética , Humanos , Leucemia Mieloide Aguda/metabolismo , Fatores Inibidores da Migração de Macrófagos/biossíntese , Fatores Inibidores da Migração de Macrófagos/genética , Pessoa de Meia-Idade , Proteínas Proto-Oncogênicas c-myc/biossíntese , Proteínas Proto-Oncogênicas c-myc/genética , Regulação para CimaRESUMO
A novel whole cell bacterial biosensor, which emits light in response to the active metabolite of cytosine arabinoside (ara-C, cytarabine), ara-CTP, has been investigated and verified. The biosensor has been formulated as an ex vivo assay, designed for peripheral blood or bone marrow cells, which can produce a clinical result within a working day. The nucleoside analogue ara-C is a key agent for treatment of acute myeloid leukaemia (AML); treatment decisions are made rapidly with AML, patients often receiving same-day commencement of chemotherapy. Currently no rapid predictive test is available to select appropriate therapy for patients prior to treatment. Experiments were designed to determine optimal assay conditions using leukaemic cell lines. We observed a significant increase (~15 fold) in bioluminescence signal compared to control after 8-h incubation of the biosensor with ara-C. This corresponded to a >2-log increase in light output per bacterial cell. Interestingly, bioluminescence conferred a survival advantage to the bacteria following ara-C treatment. The assay is sensitive (lower limit of quantitation of 0.05 µM), selective, accurate (≤ 15% RE) and precise (≤ 15% coefficient of variation) over a linear concentration range of ara-CTP (0.05-0.5 µM), and detection is independent of reaction volume. Recovery of added standard was tested using ex vivo patient leukaemic cells (n=5). Stability studies on lyophilized bacterial biosensor were performed to ensure maintenance of performance over 12 months. The biosensor assay could be invaluable to the clinician, assisting with treatment selection, and potentially mitigating the risks of resistance and toxicity observed with this drug.
Assuntos
Arabinofuranosilcitosina Trifosfato/isolamento & purificação , Técnicas Biossensoriais , Citarabina/isolamento & purificação , Leucemia Mieloide Aguda/sangue , Arabinofuranosilcitosina Trifosfato/sangue , Biomarcadores Tumorais/sangue , Humanos , Leucemia Mieloide Aguda/patologia , Limite de Detecção , Medições LuminescentesRESUMO
This study evaluates an in vitro biosensor assay capable of detecting the intracellular levels of the tri-phosphorylated form of cytarabine (Ara-CTP) within one working day. The biosensor predicted the response of seven leukaemic cell lines with varying known sensitivities to cytarabine alone and in combination with fludarabine. High-performance liquid chromatography (HPLC), 3-day assessment of cellular viable mass, and flow cytometric assessment of apoptosis were used to validate biosensor performance. A correlation between the biosensor results and Ara-CTP quantitation by HPLC was confirmed (R=0.972). The biosensor was also capable of detecting enhanced accumulation of Ara-CTP following sequential pre-treatment of leukaemic cells with cytarabine ± fludarabine.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia , Arabinofuranosilcitosina Trifosfato/análise , Técnicas Biossensoriais/métodos , Citarabina/farmacologia , Leucemia/patologia , Vidarabina/análogos & derivados , Apoptose/efeitos dos fármacos , Proteínas de Bactérias/análise , Linhagem Celular Tumoral , Células HL-60 , Humanos , Células K562 , Leucemia/diagnóstico , Leucemia/tratamento farmacológico , Medições Luminescentes/métodos , Proteínas Luminescentes/análise , Resultado do Tratamento , Vidarabina/farmacologiaRESUMO
Background: Patients admitted to internal medicine services receive multiple drugs and thus are at risk of medication errors. Aim: To determine the frequency of medication errors (ME) among patients admitted to an internal medicine service of a high complexity hospital. Material and Methods: A prospective observational study conducted in 225 patients admitted to an internal medicine service. Each stage of drug utilization system (prescription, transcription, dispensing, preparation and administration) was directly observed by trained pharmacists not related to hospital staff during three months. ME were described and categorized according to the National Coordinating Council for Medication Error Reporting and Prevention. In each stage of medication use, the frequency of ME and their characteristics were determined. Results: A total of 454 drugs were prescribed to the studied patients. In 138 (30,4%) indications, at least one ME occurred, involving 67 (29,8%) patients. Twenty four percent of detected ME occurred during administration, mainly due to wrong time schedules. Anticoagulants were the therapeutic group with the highest occurrence of ME. Conclusions: At least one ME occurred in approximately one third of patients studied, especially during the administration stage. These errors could affect the medication safety and avoid achieving therapeutic goals. Strategies to improve the quality and safe use of medications can be implemented using this information.